Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 4Neoplasm Metastasis 3Rectal Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophagogastric Cancer 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Blast Crisis 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × STA 9090 × Clear all
NCT01562015 2015-05-20

CHIARA

Synta Pharmaceuticals Corp.

Phase 2 Completed
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01031225 2014-09-19

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Synta Pharmaceuticals Corp.

Phase 2 Completed
113 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡